Complementary therapies for inflammation.
Wang
Yi
Y
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D050577:Complement C3-C5 Convertases / Q000037:antagonists & inhibitors / Q000378:metabolism; D015938:Complement Membrane Attack Complex / Q000187:drug effects / Q000378:metabolism; D003165:Complement System Proteins / Q000276:immunology; D000529:Complementary Therapies; D006801:Humans; D007249:Inflammation / Q000628:therapy*; D008565:Membrane Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D044087:Receptor, Anaphylatoxin C5a; D011951:Receptors, Complement / Q000235:genetics / Q000276:immunology* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C488033:C5AR1 protein, human; D015938:Complement Membrane Attack Complex; D008565:Membrane Proteins; D044087:Receptor, Anaphylatoxin C5a; D011951:Receptors, Complement; D003165:Complement System Proteins; C481642:eculizumab; D050577:Complement C3-C5 Convertases